SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Unax Lertxundi, Arantxazu Isla Ruiz, María Ángeles Solinís Aspiazu, Saioa Domingo-Echaburu, Montserrat García, Carmelo Aguirre, Juan Carlos García-Moncó, Adverse Reactions to Antipsychotics in Parkinson Disease, Clinical Neuropharmacology, 2015, 1

    CrossRef

  2. 2
    Isabelle Beaulieu-Boire, Anthony E. Lang, Behavioral effects of levodopa, Movement Disorders, 2015, 30, 1
  3. 3
    Clive Ballard, Stuart Isaacson, Roger Mills, Hilde Williams, Anne Corbett, Bruce Coate, Rajesh Pahwa, Olivier Rascol, David J. Burn, Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis, Journal of the American Medical Directors Association, 2015,

    CrossRef

  4. 4
    Jacopo Vittoriano Bizzarri, Giancarlo Giupponi, Ignazio Maniscalco, Patrizia Schroffenegger, Andreas Conca, Hans Peter Kapfhammer, Parkinson-Krankheit und Psychosen, neuropsychiatrie, 2015, 29, 1, 1

    CrossRef

  5. 5
    Hyungjin Myra Kim, Claire Chiang, Daniel Weintraub, Lon S. Schneider, Helen Kales, Treatment changes among older patients with dementia treated with antipsychotics, International Journal of Geriatric Psychiatry, 2015, 30, 9
  6. 6
    Martin Broadstock, Clive Ballard, Anne Corbett, Novel pharmaceuticals in the treatment of psychosis in Parkinson’s disease, Expert Review of Clinical Pharmacology, 2014, 7, 6, 779

    CrossRef

  7. 7
    Jeffrey Cummings, Stuart Isaacson, Roger Mills, Hilde Williams, Kathy Chi-Burris, Anne Corbett, Rohit Dhall, Clive Ballard, Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial, The Lancet, 2014, 383, 9916, 533

    CrossRef

  8. 8
    Leora L Borek, Joseph H Friedman, Treating psychosis in movement disorder patients: a review, Expert Opinion on Pharmacotherapy, 2014, 15, 11, 1553

    CrossRef

  9. 9
    Barbara Connolly, Susan H. Fox, Treatment of Cognitive, Psychiatric, and Affective Disorders Associated with Parkinson’s Disease, Neurotherapeutics, 2014, 11, 1, 78

    CrossRef

  10. 10
    Jennifer G. Goldman, Samantha Holden, Treatment of Psychosis and Dementia in Parkinson’s Disease, Current Treatment Options in Neurology, 2014, 16, 3

    CrossRef

  11. 11
    David Hubbard, Uli Hacksell, Krista McFarland, Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson’s disease and Parkinson’s disease psychosis, Behavioural Pharmacology, 2013, 24, 7, 628

    CrossRef

  12. 12
    Heinz Reichmann, Christine Schneider, Neuropsychiatrische Störungen beachten, DNP - Der Neurologe und Psychiater, 2013, 14, 6, 42

    CrossRef

  13. 13
    ROSA QUELHAS, Psychiatric Care in Parkinson’s Disease, Journal of Psychiatric Practice, 2013, 19, 2, 118

    CrossRef

  14. You have free access to this content14
    J. J. Ferreira, R. Katzenschlager, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder, A. Schapira, A. Berardelli, W. H. Oertel, Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease, European Journal of Neurology, 2013, 20, 1
  15. 15
    David Salat, Eduardo Tolosa, Handbook of Parkinson’s Disease, 2013,

    CrossRef

  16. 16
    David Salat, Eduardo Tolosa, Handbook of Parkinson's Disease, Fifth Edition, 2013,

    CrossRef

  17. 17
    Yoshikuni Mizuno, An update on the management of juvenile and young-onset Parkinson’s disease, Future Neurology, 2012, 7, 5, 581

    CrossRef

  18. 18
    Hae-Won Shin, Sun Ju Chung, Drug-Induced Parkinsonism, Journal of Clinical Neurology, 2012, 8, 1, 15

    CrossRef

  19. 19
    José Luis López-Sendón, María Angeles Mena, Justo García de Yébenes, Drug-Induced Parkinsonism in the Elderly, Drugs & Aging, 2012, 29, 2, 105

    CrossRef

  20. You have free access to this content20
    Lothar Burghaus, Carsten Eggers, Lars Timmermann, Gereon R. Fink, Nico J. Diederich, Hallucinations in Neurodegenerative Diseases, CNS Neuroscience & Therapeutics, 2012, 18, 2
  21. 21
    &NA;, Manage drug-induced parkinsonism through early recognition of the condition and discontinuation of the causative agent, Drugs & Therapy Perspectives, 2012, 28, 12, 20

    CrossRef

  22. 22
    Manage drug-induced parkinsonism through early recognition of the condition and discontinuation of the causative agent, Drugs & Therapy Perspectives, 2012, 28, 12, 20

    CrossRef

  23. 23
    Yoland Smith, Thomas Wichmann, Stewart A Factor, Mahlon R DeLong, Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa, Neuropsychopharmacology, 2012, 37, 1, 213

    CrossRef

  24. 24
    Francisco Portillo Núñez, Laura Rodríguez Uriarte, Cristina Alonso Villaverde, Enrique Vadillo Movillán, Juan Miguel Rodríguez Losantos, Jose Miguel Cebamanos Martín, Parkinsonismo secundario a la asociación de metronidazol y quetiapina, Psiquiatría Biológica, 2012, 19, 2, 62

    CrossRef

  25. 25
    David A. Gallagher, Anette Schrag, Psychosis, apathy, depression and anxiety in Parkinson's disease, Neurobiology of Disease, 2012, 46, 3, 581

    CrossRef

  26. 26
    Arvid Rongve, Eirik Auning, Uwe Ehrt, Dag Årsland, Psykose ved Parkinsons sykdom, Tidsskrift for Den norske legeforening, 2012, 132, 2, 155

    CrossRef

  27. 27
    Supplement 4: Canadian Guidelines on Parkinson's Disease, The Canadian Journal of Neurological Sciences, 2012, 39, S4, S1

    CrossRef

  28. 28
    K. Bloomfield, L. MacDonald, G. Finucane, B. Snow, R. Roxburgh, Use of antipsychotic medications in patients with Parkinson's disease at Auckland City Hospital, Internal Medicine Journal, 2012, 42, 7
  29. 29
    Luis Pintor, Francesc Valldeoriola, Eva Baillés, María José Martí, Armando Muñiz, Eduard Tolosa, Ziprasidone Versus Clozapine in the Treatment of Psychotic Symptoms in Parkinson Disease, Clinical Neuropharmacology, 2012, 35, 2, 61

    CrossRef

  30. 30
    Grace Liang, James Tetrud, Parkinson's Disease, Second Edition, 2012,

    CrossRef

  31. 31
    Jennifer G Goldman, Christina L Vaughan, Christopher G Goetz, An update expert opinion on management and research strategies in Parkinson's disease psychosis, Expert Opinion on Pharmacotherapy, 2011, 12, 13, 2009

    CrossRef

  32. 32
    Dag Aarsland, Uwe Ehrt, Irena Rektorova, Cognitive and psychiatric disturbances in Parkinson’s disease, Aging Health, 2011, 7, 1, 123

    CrossRef

  33. 33
    Avrom L. Kurtz, Daniel I. Kaufer, Dementia in Parkinson’s Disease, Current Treatment Options in Neurology, 2011, 13, 3, 242

    CrossRef

  34. 34
    Michael J. Aminoff, Chad W. Christine, Joseph H. Friedman, Kelvin L. Chou, Kelly E. Lyons, Rajesh Pahwa, Bastian R. Bloem, Sotirios A. Parashos, Catherine C. Price, Irene A. Malaty, Robert Iansek, Ivan Bodis-Wollner, Oksana Suchowersky, Wolfgang H. Oertel, Jorge Zamudio, Joyce Oberdorf, Peter Schmidt, Michael S. Okun, Management of the hospitalized patient with Parkinson’s disease: Current state of the field and need for guidelines, Parkinsonism & Related Disorders, 2011, 17, 3, 139

    CrossRef

  35. 35
    Joseph H Friedman, Managing psychosis in Parkinson’s disease, Neurodegenerative Disease Management, 2011, 1, 3, 217

    CrossRef

  36. 36
    Alana Iglewicz, Thomas W. Meeks, Dilip V. Jeste, New Wine in Old Bottle: Late-life Psychosis, Psychiatric Clinics of North America, 2011, 34, 2, 295

    CrossRef

  37. 37
    Daniel Weintraub, David J. Burn, Parkinson's disease: The quintessential neuropsychiatric disorder, Movement Disorders, 2011, 26, 6
  38. 38
    Klaus Seppi, Daniel Weintraub, Miguel Coelho, Santiago Perez-Lloret, Susan H. Fox, Regina Katzenschlager, Eva-Maria Hametner, Werner Poewe, Olivier Rascol, Christopher G. Goetz, Cristina Sampaio, The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease, Movement Disorders, 2011, 26, S3
  39. 39
    Philippe Huot, Susan H. Fox, Jonathan M. Brotchie, The serotonergic system in Parkinson's disease, Progress in Neurobiology, 2011, 95, 2, 163

    CrossRef

  40. 40
    Enrique Álvarez, Consuelo Almenar, Neurofarmacología Contemporánea, 2011,

    CrossRef

  41. 41
    Stanley Fahn, Joseph Jankovic, Mark Hallett, Principles and Practice of Movement Disorders, 2011,

    CrossRef

  42. 42
    Lindy D. Wood, Clinical Review and Treatment of Select Adverse Effects of Dopamine Receptor Agonists in Parkinsonʼs Disease, Drugs & Aging, 2010, 27, 4, 295

    CrossRef

  43. 43
    Alissa A. Thomas, Joseph H. Friedman, Current Use of Clozapine in Parkinson Disease and Related Disorders, Clinical Neuropharmacology, 2010, 33, 1, 14

    CrossRef

  44. 44
    Marty L. Eng, Timothy E. Welty, Management of hallucinations and psychosis in Parkinson's disease, The American Journal of Geriatric Pharmacotherapy, 2010, 8, 4, 316

    CrossRef

  45. 45
    Roberto Ceravolo, Carlo Rossi, Lorenzo Kiferle, Ubaldo Bonuccelli, Nonmotor symptoms in Parkinson’s disease: the dark side of the moon, Future Neurology, 2010, 5, 6, 851

    CrossRef

  46. 46
    Stanley Fahn, Parkinson's disease: 10 years of progress, 1997–2007, Movement Disorders, 2010, 25, S1
  47. 47
    Herbert Y Meltzer, Roger Mills, Stephen Revell, Hilde Williams, Ann Johnson, Daun Bahr, Joseph H Friedman, Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease Psychosis, Neuropsychopharmacology, 2010, 35, 4, 881

    CrossRef

  48. 48
    Joseph H. Friedman, Recommendations on the Drug Treatment of Psychosis in Parkinson's Disease, The American Journal of Medicine, 2010, 123, 4, e19

    CrossRef

  49. 49
    Shen-Yang Lim, Anthony E. Lang, The nonmotor symptoms of Parkinson's disease—An overview, Movement Disorders, 2010, 25, S1
  50. 50
    David J. Burn, The Treatment of Cognitive Impairment Associated with Parkinson's Disease, Brain Pathology, 2010, 20, 3
  51. 51
    John Y. Fang, UPDATE ON THE MEDICAL MANAGEMENT OF PARKINSON DISEASE, CONTINUUM: Lifelong Learning in Neurology, 2010, 16, 96

    CrossRef

  52. 52
    Shamim H. Nejad, Joshua L. Roffman, Karsten Kueppenbender, Felicia A. Smith, Jeff C. Huffman, Theodore A. Stern, Massachusetts General Hospital Handbook of General Hospital Psychiatry, 2010,

    CrossRef

  53. 53
    Daniel Weintraub, MOVEMENT DISORDERS 4, 2010,

    CrossRef

  54. 54
    Matthias Löhle, Alexander Storch, Heinz Reichmann, Beyond tremor and rigidity: non-motor features of Parkinson’s disease, Journal of Neural Transmission, 2009, 116, 11, 1483

    CrossRef

  55. 55
    Josè Martin Rabey, Hallucinations and psychosis in Parkinson's disease, Parkinsonism & Related Disorders, 2009, 15, S105

    CrossRef

  56. 56
    Nico J. Diederich, Gilles Fénelon, Glenn Stebbins, Christopher G. Goetz, Hallucinations in Parkinson disease, Nature Reviews Neurology, 2009, 5, 6, 331

    CrossRef

  57. 57
    Ken-ichi Fujimoto, Management of non-motor complications in Parkinson’s disease, Journal of Neurology, 2009, 256, S3, 299

    CrossRef

  58. 58
    Mark Stacy, Medical Treatment of Parkinson Disease, Neurologic Clinics, 2009, 27, 3, 605

    CrossRef

  59. 59
    Victoria Chang, Joseph H Friedman, Motor side effects of atypical antipsychotic drugs, Therapy, 2009, 6, 2, 249

    CrossRef

  60. 60
    Heinz Reichmann, Christine Schneider, Matthias Löhle, Non-motor features of Parkinson's disease: depression and dementia, Parkinsonism & Related Disorders, 2009, 15, S87

    CrossRef

  61. 61
    Ariane Park, Mark Stacy, Non-motor symptoms in Parkinson’s disease, Journal of Neurology, 2009, 256, S3, 293

    CrossRef

  62. 62
    Mehrul Hasnain, W. Victor R. Vieweg, Mark S. Baron, Mary Beatty-Brooks, Antony Fernandez, Anand K. Pandurangi, Pharmacological Management of Psychosis in Elderly Patients with Parkinsonism, The American Journal of Medicine, 2009, 122, 7, 614

    CrossRef

  63. 63
    HUBERT H. FERNANDEZ, MICHAEL S. OKUN, RAMON L. RODRIGUEZ, IRENE A. MALATY, JANET ROMRELL, ANQI SUN, SAMUEL S. WU, SANDEEP PILLARISETTY, ANAND NYATHAPPA, STEPHAN EISENSCHENK, QUETIAPINE IMPROVES VISUAL HALLUCINATIONS IN PARKINSON DISEASE BUT NOT THROUGH NORMALIZATION OF SLEEP ARCHITECTURE: RESULTS FROM A DOUBLE-BLIND CLINICAL-POLYSOMNOGRAPHY STUDY, International Journal of Neuroscience, 2009, 119, 12, 2196

    CrossRef

  64. 64
    Susan H. Fox, Rosalind Chuang, Jonathan M. Brotchie, Serotonin and Parkinson's disease: On movement, mood, and madness, Movement Disorders, 2009, 24, 9
  65. 65
    William J. Weiner, What do clinical trials tell us about treating patients?, Parkinsonism & Related Disorders, 2009, 15, S34

    CrossRef

  66. 66
    Bradley J. Robottom, William J. Weiner, Neurobiology of Dementia, 2009,

    CrossRef

  67. 67
    Kelvin L. Chou, Adverse Events from the Treatment of Parkinson's Disease, Neurologic Clinics, 2008, 26, 3, 65

    CrossRef

  68. 68
    Rachel Goldmann Gross, Andrew Siderowf, Howard I. Hurtig, Cognitive Impairment in Parkinson’s Disease and Dementia with Lewy Bodies: A Spectrum of Disease, Neurosignals, 2008, 16, 1, 24

    CrossRef

  69. 69
    Shen-Yang Lim, Andrew H. Evans, Janis M. Miyasaki, Impulse Control and Related Disorders in Parkinson's Disease, Annals of the New York Academy of Sciences, 2008, 1142, 1
  70. 70
    Daniel D. Truong, Roongroj Bhidayasiri, Erik Wolters, Management of non-motor symptoms in advanced Parkinson disease, Journal of the Neurological Sciences, 2008, 266, 1-2, 216

    CrossRef

  71. 71
    Laura B Zahodne, Hubert H Fernandez, Pathophysiology and Treatment of Psychosis in Parkinson’s Disease, Drugs & Aging, 2008, 25, 8, 665

    CrossRef

  72. 72
    D. Paleacu, Y. Barak, I. Mirecky, D. Mazeh, Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: a 6-week, double-blind, placebo-controlled study, International Journal of Geriatric Psychiatry, 2008, 23, 4
  73. 73
    Ubaldo Bonuccelli, Roberto Ceravolo, The safety of dopamine agonists in the treatment of Parkinson's disease, Expert Opinion on Drug Safety, 2008, 7, 2, 111

    CrossRef

  74. 74
    Miguel Coelho, Joaquim Ferreira, Mário Rosa, Cristina Sampaio, Treatment options for non-motor symptoms in late-stage Parkinson's disease, Expert Opinion on Pharmacotherapy, 2008, 9, 4, 523

    CrossRef

  75. 75
    Oraporn Sitburana, Susan Rountree, William G. Ondo, Weight change in Parkinson and Alzheimer patients taking atypical antipsychotic drugs, Journal of the Neurological Sciences, 2008, 272, 1-2, 77

    CrossRef

  76. 76
    Textbook of Clinical Neuropsychiatry Second edition, 2008,

    CrossRef

  77. 77
    Daniel Weintraub, Matthew B Stern, Intervening in the neuropsychiatric features of Parkinson’s disease, Expert Review of Neurotherapeutics, 2007, 7, 6, 699

    CrossRef

  78. 78
    Leora L Borek, Kelvin L Chou, Joseph H Friedman, Management of the behavioral aspects of Parkinson’s disease, Expert Review of Neurotherapeutics, 2007, 7, 6, 711

    CrossRef

  79. 79
    Marco Onofrj, Astrid Thomas, Laura Bonanni, New approaches to understanding hallucinations in Parkinson’s disease: phenomenology and possible origins, Expert Review of Neurotherapeutics, 2007, 7, 12, 1731

    CrossRef

  80. 80
    Mark Stacy, Joseph Jankovic, Overview of the Medical Treatment of the Non-Motor and Non-Dopaminergic Features of Parkinson's Disease,
  81. 81
    Joseph H. Friedman, Psychosis in Parkinson's Disease,
  82. 82
    Friederike Sixel-Döring, Claudia Trenkwalder, Sleep Disorders in Parkinson's Disease,
  83. 83
    Murat Emre, Treatment of Dementia Associated with Parkinson's Disease,